A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2019
Price : $35 *
At a glance
- Drugs Indoximod (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NewLink Genetics Corporation
- 21 Feb 2019 Status changed from active, no longer recruiting to completed.
- 09 Nov 2018 Results presented in the NewLink Genetics Corporation media release.
- 09 Nov 2018 According to a NewLink Genetics Corporation media release, results form this trial are being presented today and tomorrow at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington D.C.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History